Skip to content

The study to evaluate the efficacy and safety of using Platelet-rich plasma for treating nasolabial folds in Thailand

The study to evaluate the efficacy and safety of using Platelet-rich plasma for treating nasolabial folds in Thailand

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220515002
Enrollment
50
Registered
2022-05-15
Start date
2022-01-03
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy human volunteers PRP, Platelet-rich plasma, nasolabial fold.

Interventions

20 ml of blood was drawn from volunteer and the blood was centrifuged to get PRP by using RegenLab PRP tube. The PRP was injected into nasolabial fold. This process was repeated for 2 more times every
Active Comparator Device,Active Comparator Device

Sponsors

Dermatologic Surgery, Dermatology department, Siriraj hospital, Thailand
Lead Sponsor
ASTRACO MEDICAL NETWORKS LTD,Terumo Thailand
Collaborator

Eligibility

Sex/Gender
All
Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Have nasolabial fold 2. Thais 3. Healthy

Exclusion criteria

Exclusion criteria: 1. pregnant or lactating woman 2. Having severe acnes 3. Having the skin disease around the treated area 4. Using an energy-based device or other interventions around treated area 6 months prior

Design outcomes

Primary

MeasureTime frame
Nasolabial fold improvement Before intervention, every treatment visits, 14 days, 1, 2, 3, and 6 months after the intervention Level of improvement measure from vectra M1,Subject self assessment score Every treatment visits, 14 days, 1, 2, 3, and 6 months after the intervention percentage of Subject self assessment score,Physicians assessment score Every treatment visits, 14 days, 1, 2, 3, and 6 months after the intervention percentage of Physicians assessment score

Secondary

MeasureTime frame
Pain score immediate after the intervention Visual analogue scale (0-10),Adverse reaction Every treatment visits, 14 days, 1, 2, 3, and 6 months after the intervention Descriptive report

Countries

Thailand

Contacts

Public ContactSurachet Sirisuthivoranunt

Faculty of Medicine Siriraj Hospital, Mahidol University

siri.surachet@gmail.com024199933

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026